ESR1 and breast carcinoma: Like FOXA1, GRHL2 may act as a pioneer factor, promoting chromatin accessibility and GRHL2 has been found to co-occupy enhancer elements with FOXA1, GATA3, and ER⍺ to regulate ER⍺ signaling output in hormone receptor positive breast cancer [34–37].